Announced today that pacritinib offers been granted Fast Monitor designation by the U.

CTI BioPharma’s pacritinib granted FDA Fast Track designation for treatment of myelofibrosis CTI BioPharma Corp. announced today that pacritinib offers been granted Fast Monitor designation by the U .S. Food and Drug Administration for the treatment of intermediate and high risk myelofibrosis, including but not limited to individuals with disease related thrombocytopenia, patients going through treatment emergent thrombocytopenia on additional JAK2 therapy or sufferers who are intolerant to or whose symptoms are sub-optimally managed on various other JAK2 therapy. Pacritinib can be an oral tyrosine kinase inhibitor with dual activity against FLT3 and JAK2. The drug candidate has been evaluated in two Phase 3 clinical trials currently, known as the PERSIST system, for individuals with myelofibrosis.

This article released in the Journal of Discomfort and Symptom Management ( detailed the scholarly research led by principal investigator, Thomas J. Smith, M.D., Endowed Chair of Palliative Care Study and Medical Director of the Thomas Palliative Care Device Virginia Commonwealth University’s Massey Cancer tumor Center. Calmare, which treats chronic oncologic and neuropathic pain, received FDA qualification for product sales in the U.S. In 2009 2009.S. Independent medical study, to specifically examine the ability of CTTC’s Calmare pain therapy treatment to diminish pain connected with CIPN.